Vicente Samano

Title: Vicente Samano: Innovator in Selective Estrogen Receptor Modulation

Introduction

Vicente Samano is a notable inventor based in Durham, NC (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that serve as selective estrogen receptor modulators. With a total of 2 patents, his work has implications for various therapeutic applications.

Latest Patents

Samano's latest patents include innovative compounds that have the potential to revolutionize treatment options. One of his patents focuses on triphenylethylene compounds as selective estrogen receptor modulators. These compounds are designed for a variety of therapeutic uses, particularly as novel prodrugs that effectively deliver parent compounds for selective estrogen receptor modulation. Another significant patent involves derivatives of 1-(oxoaminoacetyl) pentylcarbamate, which act as cathepsin K inhibitors for the treatment of bone loss. This invention describes heterocycle substituted ketoamide derivatives that are useful in treating disorders such as osteoporosis, which is associated with an imbalance between bone resorption and formation.

Career Highlights

Vicente Samano is currently associated with SmithKline Beecham Corporation, where he continues to advance his research and development efforts. His work has garnered attention for its potential to address critical health issues related to bone density and hormonal regulation.

Collaborations

Some of his notable coworkers include John Albert Ray and John Fred Eaddy, III. Their collaborative efforts contribute to the innovative environment at SmithKline Beecham Corporation.

Conclusion

Vicente Samano's contributions to the field of medicinal chemistry highlight his role as an inventor dedicated to improving therapeutic options. His patents reflect a commitment to addressing significant health challenges through innovative solutions.